Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma

被引：61

作者：

Haioun, C. ^{[1
,2
]}

Mounier, N. ^{[3
]}

Emile, J. F. ^{[4
]}

Ranta, D. ^{[5
]}

Coiffier, B. ^{[6
]}

Tilly, H. ^{[7
]}

Recher, C. ^{[8
]}

Ferme, C. ^{[9
]}

Gabarre, J. ^{[10
]}

Herbrecht, R. ^{[11
]}

Morchhauser, F. ^{[12
]}

Gisselbrecht, C. ^{[13
]}

机构：

[1] Grp Hosp Henri Mondor Chenevier, AP HP, Ctr Hosp Univ, Serv Hematol, Creteil, France

[2] Univ Paris 12, Creteil, France

[3] Ctr Hosp Univ Archet 1, Serv Oncohematol, Nice, France

[4] Hop Ambroise Pare, AP HP, Serv Pathol, Paris, France

[5] Ctr Hosp Univ Nancy Brabois, Serv Hematol & Med Interne, Vandoeuvre Les Nancy, France

[6] Hosp Civils Lyon, Hop Lyon Sud, Serv Hematol, Pierre Benite, France

[7] Ctr Henri Becquerel, Dept Hematol, F-76038 Rouen, France

[8] CHU Purpan, Serv Hematol, Toulouse, France

[9] Inst Gustave Roussy, Serv Hematol, Villejuif, France

[10] Grp Hosp Pitie Salpetriere, AP HP, Ser Hematol Clin, F-75634 Paris, France

[11] CHU Strasbourg, Dept Hematol & Oncol, F-67000 Strasbourg, France

[12] CHU Lille, Serv Malad Sang, F-59037 Lille, France

[13] Hop St Louis, AP HP, Serv Hematooncol Adulte, Paris, France

来源：

ANNALS OF ONCOLOGY | 2009年 / 20卷 / 12期

关键词：

autologous transplantation; diffuse large B-cell lymphoma; poor-risk lymphoma; rituximab; NON-HODGKINS-LYMPHOMA; BONE-MARROW-TRANSPLANTATION; AGGRESSIVE LYMPHOMA; PHASE-II; EMISSION-TOMOGRAPHY; CHOP CHEMOTHERAPY; RESPONSE CRITERIA; ELDERLY-PATIENTS; PLUS RITUXIMAB; ESCALATED CHOP;

D O I：

10.1093/annonc/mdp237

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Materials and methods: Four hundred and seventy-six patients < 60 years old with newly diagnosed CD20+ DLBCL were randomised to induction with ACE or ACVBP. Three hundred and thirty responders received HDT followed by ASCT. After ASCT, 269 patients were re-randomised to receive either maintenance rituximab or observation alone. Randomisation was stratified by the quality of response to ASCT. The primary end point of this study was event-free survival (EFS). Results: At a median of 4 years' follow-up from the second randomisation, there was a trend (P = 0.1) towards increased EFS for patients who received rituximab compared with observation. Conclusion: The type of induction therapy (ACVBP or ACE) did not significantly affect overall survival at a median 51 months' follow-up.

引用

页码：1985 / 1992

页数：8

共 32 条

[1]

[Anonymous], 1993, N ENGL J MED

[2]

Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma:: a prospective study from the GEL-TAMO Study Group [J].

Arranz, Reyes ;

Conde, Eulogio ;

Grande, Carlos ;

Mateos, Maria Victoria ;

Gandarillas, Marco ;

Albo, Carmen ;

Lahuerta, Juan J. ;

Fernandez-Ranada, Jose M. ;

Hernandez, Miguel T. ;

Alonso, Natalia ;

Vela, Jose A. Garcia ;

Garzon, Sebastian ;

Rodriguez, Jose ;

Caballero, Dolores .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2008, 80 (03) :227-235

[3]

Rituximab combined to ACVBP (R-ACVBP) supported by pegfilgrastim as a new inductive treatment followed by high-dose consolidative autotransplantation (HDC) for poor risk diffuse large B-cell lymphoma (DLBCL) in first-line. Results of LNH 03-39B. A GELA study [J].

Belhadj, Karim ;

Jais, Jean-Philipp ;

Feugier, Pierre ;

Gisselbrecht, Christian ;

Recher, Christian ;

Casasnova, Olivier ;

Coiffier, Bertrand ;

Sebban, Catherine ;

Delmer, Alain ;

Morschhauser, Franck ;

Canioni, Daniele ;

Tilly, Herve ;

Haioun, Corinne .

BLOOD, 2007, 110 (11) :1007A-1007A

[4]

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas [J].

Cheson, BD ;

Horning, SJ ;

Coiffier, B ;

Shipp, MA ;

Fisher, RI ;

Connors, JM ;

Lister, TA ;

Vose, J ;

Grillo-López, A ;

Hagenbeek, A ;

Cabanillas, F ;

Klippensten, D ;

Hiddemann, W ;

Castellino, R ;

Harris, NL ;

Armitage, JO ;

Carter, W ;

Hoppe, R ;

Canellos, GP .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) :1244-1253

[5]

Revised response criteria for malignant lymphoma [J].

Cheson, Bruce D. ;

Pfistner, Beate ;

Juweid, Malik E. ;

Gascoyne, Randy D. ;

Specht, Lena ;

Horning, Sandra J. ;

Coiffier, Bertrand ;

Fisher, Richard I. ;

Hagenbeek, Anton ;

Zucca, Emanuele ;

Rosen, Steven T. ;

Stroobants, Sigrid ;

Lister, T. Andrew ;

Hoppe, Richard T. ;

Dreyling, Martin ;

Tobinai, Kensei ;

Vose, Julie M. ;

Connors, Joseph M. ;

Federico, Massimo ;

Diehl, Volker .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) :579-586

[6]

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [J].

Coiffier, B ;

Lepage, E ;

Brière, J ;

Herbrecht, R ;

Tilly, H ;

Bouabdallah, R ;

Morel, P ;

Van den Neste, E ;

Salles, G ;

Gaulard, P ;

Reyes, F ;

Gisselbrecht, C .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :235-242

[7]

Coiffier B, 1998, BLOOD, V92, P1927

[8]

Coiffier Bertrand, 2005, Curr Opin Hematol, V12, P259, DOI 10.1097/01.moh.0000168519.98990.94

[9]

A phase II trial of rituximab as adjuvant to intensive sequential chemotherapyin patients under 60 years with untreated poor-prognosis diffuse large B-cell lymphoma [J].

Coso, D. ;

Sebban, C. ;

Boulat, O. ;

Biron, P. ;

Rey, J. ;

Aurran, T. ;

Chabannon, C. ;

Xerri, L. ;

Chetaille, B. ;

Esterni, B. ;

Ivanov, V. ;

Stoppa, A. M. ;

de Collela, J. M. Schiano ;

Gastaut, J. A. ;

Maraninchi, D. ;

Bouabdallah, R. .

BONE MARROW TRANSPLANTATION, 2006, 38 (03) :217-222

[10]

A prospective study of intensive induction therapy with high-dose consolidation in patients with aggressive non-Hodgkin's lymphoma and two or three adverse prognostic factors [J].

Dumontet, C ;

Thieblemont, C ;

Espinouse, D ;

Bouafia, F ;

Hequet, O ;

Salles, G ;

Coiffier, B .

LEUKEMIA, 2000, 14 (12) :2159-2165

← 1 2 3 4 →